GET DAILY SIGNALSWhy DXCM (+25% YTD) Stands Out Against PODD in Diabetes Technology
Key Takeaways
- Both DXCM and PODD operate in the diabetes technology market, but their recent trajectories have diverged sharply.
- DXCM delivered a beat-and-raise quarter, expanding margins and raising its 2026 outlook, while PODD beat on earnings but guided 2027 growth below its prior framework.
- Tickeron AI Verdict: The AI currently favors DXCM, citing stronger trend consistency, positive catalysts, and more stable relative positioning versus PODD.
- For more context on each name, explore DXCM Major News and DXCM Today's Price Move, as well as PODD Major News and PODD Today's Price Move.
- To see how AI is applying these signals in live trading, explore the Trending AI Robots section.
Introduction
DexCom (DXCM) and Insulet (PODD) are two of the most closely watched names in diabetes care technology, yet they compete in adjacent rather than identical niches. DexCom is the leading maker of continuous glucose monitoring (CGM) sensors, while Insulet produces the Omnipod tubeless insulin delivery system. Both address the large and growing type 2 diabetes opportunity and increasingly integrate with each other's devices. This stock comparison is most relevant to investors seeking exposure to medical technology growth, as well as traders tracking relative performance and momentum shifts in the healthcare device sector. Recent quarters have highlighted meaningful differences in market positioning between the two. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
DXCM Overview and Recent Performance
DXCM designs and commercializes CGM systems used to manage diabetes and broader metabolic health. Recent weeks have been constructive for the stock, which has gained roughly 25% year-to-date and rebounded sharply after a difficult 2025. In its latest quarterly report, DexCom posted revenue of about $1.34 billion, up roughly 11% year over year, with U.S. sales growing around 14% and adjusted earnings per share (EPS) exceeding consensus. Gross margin expanded several hundred basis points on manufacturing efficiencies and the ramp of its G7 15 Day sensor.
Sentiment has been supported by the publication of the CONNECT trial in the New England Journal of Medicine, which strengthens the clinical case for CGM use among non-insulin type 2 patients and underpins a potential Medicare coverage expansion. Management raised its full-year revenue guidance and authorized an additional $1 billion buyback, reinforcing confidence in the growth trajectory.
PODD Overview and Recent Performance
PODD develops and manufactures the Omnipod platform, a tubeless, wearable insulin delivery system. The company recently reported a strong quarter, with revenue of about $842 million, up roughly 19% year over year, and adjusted EPS that meaningfully beat estimates. Insulet also narrowed its 2026 revenue growth outlook toward the upper end of its prior range and announced a $1 billion increase to its share repurchase authorization.
Despite these results, the stock has come under pressure, trading well below its 52-week high reached in late 2025. The main headwind was forward guidance: management indicated 2027 growth may come in modestly below its earlier mid-teens framework, citing tougher comparisons, product-launch timing, and expectations of ceding a few share points to new competitors. This cautious outlook has weighed on market positioning even as underlying profitability continues to improve.
Head-to-Head Comparison
The clearest contrast is in recent momentum. DXCM has been climbing within a recovery trend, while PODD has pulled back significantly from its highs despite strong quarterly execution. On business model, DexCom benefits from a recurring, sensor-based revenue stream and a broader push into non-insulin type 2 patients, whereas Insulet's growth is concentrated in a single hardware platform that faces rising competition from new patch-pump entrants.
Growth drivers also differ. DexCom's catalysts include reimbursement expansion, the G7 15 Day rollout, and upcoming product launches. Insulet's catalysts center on Omnipod 5 adoption, international expansion, and a planned Omnipod 6 launch. On risk factors, DexCom faces pricing and formulary competition in CGM, while Insulet faces a more concentrated product risk and explicit expectations of share erosion. Sector exposure is similar—both are healthcare devices—but their market sentiment and valuation setups currently point in different directions. From what I see, this divergence in positioning is worth monitoring closely.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor DXCM over PODD in the current environment. DexCom exhibits stronger trend consistency, supported by an earnings beat, raised guidance, expanding margins, and a high-profile clinical catalyst in the CONNECT study. Insulet's fundamentals remain solid, but its softer 2027 outlook and anticipated competitive share losses introduce greater uncertainty into its near-term trajectory. While both stocks carry risk, the AI's preference leans toward the name with steadier momentum and more clearly defined near-term catalysts.
Using Tickeron AI Tools for Deeper Analysis
I often turn to Tickeron’s AI Trading Bots when evaluating how different strategies might apply to names like these. The platform offers a range of automated approaches across momentum, swing, and longer-horizon setups, with performance data that helps assess fit for current conditions. It provides a practical way to see how signals are playing out without needing to build everything from scratch.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DXCM saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for DXCM moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 62 similar instances where the indicator exited the overbought zone. In 48 of the 62 cases the stock moved lower. This puts the odds of a downward move at 77%.
Technical Analysis (Indicators)
Bearish Trend Analysis
DXCM moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DXCM crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXCM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for DXCM entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DXCM's RSI Indicator exited the oversold zone, 22 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on DXCM as a result. In 62 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for DXCM just turned positive on November 02, 2026. Looking at past instances where DXCM's MACD turned positive, the stock continued to rise in 31 of 45 cases over the following month. The odds of a continued upward trend are 69%.
Following a +6.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXCM advanced for three days, in 199 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
DXCM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 27 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. DXCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.431) is normal, around the industry mean (4.142). P/E Ratio (30.779) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.332) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.988) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXCM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of medical devices and glucose monitoring systems
Industry MedicalNursingServices
Advertisement